Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.
Over the past week, Vegzelma, a bevacizumab biosimilar, launched in the United States; 2 biologics license applications (BLAs) for biosimilars were accepted for review by the FDA; and China’s regulatory agency approved a denosumab biosimilar.
Vegzelma Launch
Celltrion Healthcare launched Vegzelma (bevacizumab-adcd), a biosimilar referencing Avastin (bevacizumab), for the treatment of several cancers, according to a Big Molecule Watch report.
The biosimilar was approved by the FDA in September 2022 for use alone or in combination with other agents in patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Vegzelma is also available in Canada, Japan, and the European Union. Celltrion said that the biosimilar has been added to the Medicare reimbursement list. Vegzelma is the fourth biosimilar for Avastin to launch on the US market, following Mvasi, Zirabev, and Alymsys, the last of which launched in October 2022. Vegzelma is the first Celltiron biosimilar to launch in the United States.
2 BLA Acceptances
The FDA accepted BLAs for 2 biosimilars: a ranibizumab product and a trastuzumab candidate.
The ranibizumab biosimilar was developed by Xbrane Biopharma and if approved, will be used to treat ophthalmic conditions, including age-related macular degeneration, macular edema, and diabetic retinopathy. The biosimilar references Lucentis (ranibizumab).
Xbrane said that it expects the FDA’s review process will take about 10 months, anticipating a decision on whether the product will be approved during the first half of 2024.
The trastuzumab biosimilar (HLX02) was developed by Shanghai Henlius Biotech and if approved, will be marketed by Accord BioPharma, according to Goodwin. Trastuzumab products reference Herceptin and are used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2-overexpressing gastric or gastroesophageal junction adenocarcinoma.
The BLA included safety and efficacy data on HLX02 compared to the originator. HLX02 was also approved by the European Commission and China’s National Medical Products Administration (NMPA) in 2020. In 2021, Shanghai Henlius Biotech granted Accord Biopharma the exclusive rights for the development and commercialization of HLX02 in the U.S. and Canada.
China Approves Denosumab Biosimilar
Mabwell announced that China’s NMPA approved Mailishu, the second denosumab to receive regulatory approval in the world. The approval comes after the NMPA approved Luye Pharma Group’s Boyobei in November 2022.
Denosumab biosimilars reference Prolia/Xgeva and are used to treat and prevent bone loss and fractures associated with osteoporosis.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.